Editorial: How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma

open access
September 19. 2016

 Conclusion Use of NACT increased significantly between 2003 and 2012. In this observational study, PCS was associated with increased survival in stage IIIC, but not stage IV disease. Future studies should prospectively consider the efficacy of NACT by extent of residual disease in unselected patients.

Footnotes

• See accompanying article doi:10.1200/JCO.2016.68.1239

  Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer September 6, 2016

REFERENCES

1. 1.↵
   1. Vergote I,
   2. De Wever I,
   3. Tjalma W,
   4. et al.

   (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71:431–436.

   CrossRefMedlineGoogle Scholar
2. 2.↵
   1. Vergote I,
   2. Tropé CG,
   3. Amant F,
   4. et al.

   (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953.

   CrossRefMedlineGoogle Scholar
3. 3.↵
   1. Kehoe S,
   2. Hook J,
   3. Nankivell M,
   4. et al.

   (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet 386:249–257.

   CrossRefMedlineGoogle Scholar
4. 4.↵
   1. Meyer LA,
   2. Cronin AM,
   3. Sun CC,
   4. et al.

   Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol, doi:10.1200/JCO.2016.68.1239.
5. 5.↵
   1. Vergote I,
   2. du Bois A,
   3. Amant F,
   4. et al.

   (2013) Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol 128:6–11.

   CrossRefMedlineGoogle Scholar
6. 6.↵
   1. Risum S,
   2. Høgdall C,
   3. Loft A,
   4. et al.

   (2008) Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--A prospective study. Gynecol Oncol 108:265–270.

   CrossRefMedlineGoogle Scholar
7. 7.↵
   1. Michielsen K,
   2. Vergote I,
   3. Op de Beeck K,
   4. et al.

   (2014) Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: A clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol 24:889–901.

   CrossRefMedlineGoogle Scholar
8. 8.↵
   1. Fagotti A,
   2. Vizzielli G,
   3. De Iaco P,
   4. et al.

   (2013) A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 209:462.e1–462.e11.

   CrossRefGoogle Scholar

Related Article

• ORIGINAL REPORTS - Gynecologic Cancer: Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer

  • Larissa A. Meyer,
  • Angel M. Cronin,
  • Charlotte C. Sun,
  • Kristin Bixel,
  • Michael A. Bookman,
  • Mihaela C. Cristea,
  • Jennifer J. Griggs,
  • Charles F. Levenback,
  • Robert A. Burger,
  • Gina Mantia-Smaldone,
  • Ursula A. Matulonis,
  • Joyce C. Niland,
  • David M. O’Malley,
  • and Alexi A. Wright

  JCO JCO681239; published online on September 6, 2016;
  • [Abstract]
  • [Full Text]
  • [PDF]